RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All Non-opioids/OTC Articles

Ask the Expert: A discussion of the pain relief potential from Na1.7 Inhibitors for neuropathic pain disorders.
Recommendations concerning liver function tests for Duloxetine, prescribed for neuropathic pain.
Ask the Expert authors examine the role for low-dose ketamine for treatment of CRPS.
Pain expert offers clinical guidance to a commonly asked question about the proper, safe, and effective dose of gabapentin when treating neuropathic pain.
2016 review of current and emerging therapies for opioid-induced constipation, a common side effect of chronic opioid therapy.
To help reduce the need for opioids, IV acetaminophen could be included in the initial and perioperative pain control protocol of burn patients based on its analgesic effect, safety profile, and easy accessibility.
Forest Tennant, MD, DrPH, picks for 2016 Practical Clinical Advances in pain management—oral ketamine and metformin.
Dr. John Claude Krusz describes his protocol for the use of subanesthetic dosages of IV agents—ketamine, lidocaine, propofol—in an outpatient headache clinic.
Canadian researchers discuss 6 common concerns of patients and physicians regarding cannabis use for pain management.
Barth Wilsey, MD, shares his unique perspective and knowledge on the benefits and risks of therapeutic cannabis (medical marijuana).
Learn more about the correct dosing of different strains of medicinal cannabis used in Canada for the treatment of various pain conditions.
Skeletal muscle relaxants are commonly prescribed for the management of spasticity and spasm. Learn more about these agents used in pain management.
Guide to topical therapy for acute and chronic sports-related pain, including tendinopathies, bursitis, strains, and sprains.
Marijuana use disorder is common in the United States, is often associated with other substance use disorders, behavioral problems, and disability.
In some cases, tumor necrosis factor inhibitors (TNFi) may be the first-choice agent for patients with psoriatic arthritis. Learn why.
SHOW MAIN MENU
SHOW SUB MENU